To provide emergency assistance to States, territories, Tribal nations, and local areas affected by substance use disorder, including the use of opioids and stimulants, and to make financial assistance available to States, territories, Tribal nations, local areas, public or private nonprofit entities, and certain health providers, to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill creates a massive federal program to fight the opioid and drug addiction crisis. It establishes grant programs totaling over $10 billion annually for treatment, prevention, harm reduction, and recovery services. It also requires pharmaceutical companies and drug distributors to certify their compliance with diversion controls.
Who Benefits and How
State and local governments receive billions in grant funding to expand treatment capacity. Healthcare providers, including community health centers and nonprofits, gain access to grants for substance use treatment services. Workers with addiction issues benefit from new employment support programs. Pharmaceutical manufacturers face new accountability requirements but gain clearer compliance standards.
Who Bears the Burden and How
Drug manufacturers, distributors, and dispensers of Schedule II controlled substances must submit annual certifications to the Attorney General, with civil penalties up to $1 million for false statements. The federal government bears the cost of appropriating approximately $125 billion over 10 years.
Key Provisions
- Authorizes $3.3B annually for local area grants and $4.6B annually for state grants to address substance use disorder
- Requires manufacturers, distributors, and dispensers of Schedule II drugs to certify compliance with diversion controls
- Funds $1B annually for NIH addiction research and CDC surveillance programs
- Establishes naloxone distribution program through federal purchasing
- Prioritizes grantees with pro-labor organizing policies
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Establishes a comprehensive federal grant program to combat the opioid and substance use disorder crisis through treatment services, harm reduction, research funding, and improved regulatory oversight of controlled substances.
Key Policy Areas
Public Health, Healthcare, Drug Policy, Labor, Research
Primary Purpose
Establishes a comprehensive federal grant program to combat the opioid and substance use disorder crisis through treatment services, harm reduction, research funding, and improved regulatory oversight of controlled substances.
Policy Domains
Subtitle A - Local Area Grants
Identified Gains
Contextual inference, no direct clause citation- Local governments in high-overdose areas
- Community health centers
- Substance use treatment providers
- Individuals with substance use disorders
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal taxpayers
Contextual inference, no direct clause citation
Subtitle B - State Grants
Identified Gains
Contextual inference, no direct clause citation- State governments
- Tribal governments
- State Medicaid programs
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal taxpayers
Contextual inference, no direct clause citation
Subtitle C - Provider Grants
Identified Gains
Contextual inference, no direct clause citation- Nonprofit treatment providers
- Federally-qualified health centers
- Labor unions
- Healthcare workers
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal taxpayers
- Treatment providers opposed to unionization
Contextual inference, no direct clause citation
Subtitle D - General Provisions
Identified Gains
Contextual inference, no direct clause citation- NIH research programs
- CDC surveillance programs
- Medical schools
- Indian tribes
- Pharmaceutical research companies
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal taxpayers
Contextual inference, no direct clause citation
Controlled Substances Act Amendments
Identified Gains
Contextual inference, no direct clause citation- Federal regulators
- Public health advocates
- Communities affected by opioid crisis
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Pharmaceutical manufacturers
- Drug distributors
- Pharmacies dispensing Schedule II drugs
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMr. Raskin (for himself, Ms. Kuster, Mr. Trone, Ms. Pettersen, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
County governments in high-overdose areas, Eligible local areas with high overdose rates, High-overdose counties
Positive-direction: County governments in high-overdose areas, Eligible local areas with high overdose rates, High-overdose counties, Local governments in eligible areas, Medically underserved areas, Newly eligible local areas, State governments, State public health departments, U.S. territories, Underserved rural communities
Negative-direction: Local governments applying for grants, Local governments seeking grants, Medical examiners and coroners, State Medicaid agencies, State governments applying for grants, State regulatory agencies
Addiction medicine specialists, Federally-qualified health centers, Indian health entities
Positive-direction: Addiction medicine specialists, Federally-qualified health centers, Indian health entities, Indian health programs, Licensed private practitioners, Medicaid providers, Medicaid substance use treatment providers, Opioid treatment programs (exempt), Public health entities, Substance use treatment providers
Negative-direction: Providers opposed to unionization
Community harm reduction organizations, Federal drug control grant recipients, Harm reduction service providers
Positive-direction: Community harm reduction organizations, Harm reduction service providers, Nonprofit treatment providers, Nonprofit workforce development organizations, Peer recovery coaches and specialists, Public and nonprofit entities in underserved areas, Treatment program innovators, Voluntary treatment providers
Negative-direction: Federal drug control grant recipients, Treatment providers opposed to unionization
Centers for Disease Control and Prevention, Federal regulators (DEA, DOJ), Indian Health Service
Positive-direction: Centers for Disease Control and Prevention, Federal regulators (DEA, DOJ), Indian Health Service, Indian tribes, NIOSH, National Institutes of Health, Tribal governments
Negative-direction: Office of National Drug Control Policy
Naloxone manufacturers, Pharmaceutical company executives (CEO, president, CMO, chief counsel), Pharmaceutical research companies
Positive-direction: Naloxone manufacturers, Pharmaceutical research companies
Negative-direction: Pharmaceutical company executives (CEO, president, CMO, chief counsel), Schedule II drug manufacturers
Correctional facilities, Individuals at risk of overdose, Individuals with substance use disorder
Positive-direction: Individuals at risk of overdose, Individuals with substance use disorder, Workers with substance use disorder
Negative-direction: Correctional facilities
Drug distributor executives, Drug distributors, Schedule II drug distributors
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_attorney_general"
- → Attorney General
Key Definitions
Terms defined in this bill
The substance use planning council established under section 3402
A residential dwelling unit or other form of group housing that provides an evidence-based, peer-supported living environment for individuals undergoing or who have received substance use disorder treatment in the past 3 years
An evidence-based, professionally directed regimen including evaluation, observation, medical monitoring, and rehabilitative services to help patients reach remission and maintain recovery
A dispenser required to register under section 302(a)(2) that dispenses a Schedule II controlled substance, excluding those registered to dispense opioid agonist treatment medication
A manufacturer required to register under section 302(a)(1) that manufactures a Schedule II controlled substance
For non-individuals: CEO, president, chief medical officer, or chief counsel. For individuals: the individual themselves
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology